Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management.
Shiqi LiSanbin WangZhongtao YuanLin LiuLe LuoYu LiKun WuJia LiuChunhui YangZhimin LiLianjun ShenXun YeJiaping HeCong HanDingsong ZhangYancheng DongLihua FangYingnian ChenMartina SerschWei William CaoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The two case reports demonstrate that a standalone therapy with this novel CD7-targeted "off-the-shelf" allogeneic CAR-T therapy may provide deep and durable responses in select patients with relapsed/refractory T-ALL. GC027 might have a potential to be a promising new approach for treating refractory/relapsed T-ALL. Further studies are warranted.
Keyphrases
- induced apoptosis
- cell cycle arrest
- acute lymphoblastic leukemia
- acute myeloid leukemia
- diffuse large b cell lymphoma
- multiple myeloma
- hodgkin lymphoma
- stem cell transplantation
- cancer therapy
- bone marrow
- endoplasmic reticulum stress
- stem cells
- signaling pathway
- cell death
- oxidative stress
- helicobacter pylori infection
- human health
- replacement therapy
- liquid chromatography